Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISHL12 2022 | The use of TARC as a diagnostic biomarker in Hodgkin lymphoma

Arjan Diepstra • 26 Oct 2022
ISHL12 2022
Hodgkin Lymphoma Lymphoma

Arjan Diepstra, PhD, University of Groningen, Groningen, The Netherlands, shares some insights into why the thymus and activation-regulated chemokine (TARC) protein is an attractive biomarker in Hodgkin lymphoma (HL), highlighting that this protein is an important promoter of Hodgkin Reed-Sternberg cell growth, and is present at high levels in serum making it easily measurable. This interview took place at the 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Arjan Diepstra

0:54
The role of CD4+ T-cells in the pathogenesis of Hodgkin lymphoma
Arjan Diepstra • 26 Oct 2022
1:15
Biomarkers being explored in Hodgkin lymphoma: the role of ctDNA
Arjan Diepstra • 26 Oct 2022
1:57
Biomarkers in lymphoma
Arjan Diepstra • 15 Jun 2018

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals